CTIX Company info 09/01/2014 04:31:11 $CTIX Sorry to hear

New Post Public Reply Private Reply Replies (0) Message Board
Jake13
CTIX Company info 09/01/2014 04:31:11 $CTIX
Sorry to hear that. If they haven't told him, here are some aids right from the beginning. Sucking on ice chips regularly particularly during infusion. Rinsing several times a day with baking soda/salt water mixture. The real life saver for many is cold watermelon. Often helps with any of those nasty mouth tastes from chemo as well. The watermelon not only helps with keeping the mouth moist but also keeping body hydration to support bladder and kidney health. It can be hard to drink enough fluids and watermelon goes down easy. Prevention or lessening through these or other means beats the heck out of pain management when possible. Peace, blessings and Best Wishes for all who are affected fighting the big C.
Excellent post INH. Cheers and have a great weekend!

CTIX Stock Message Board http://investorshangout.com/Cellceutix-Corpor...TIX-87375/

Cheers BioDoc. I've been following your discussions here along with callmecrazy. Very informative. I agree with the long term sentiment. My strategy is to keep a position that will make a difference short term, as well as long term.
this error MUST be corrected, please pass it on...
=======================
Quote:
The overarching expanding reality that new kinase pathways have been and might be discovered reveal that Kevetrin's potential to accompany other existing or new multi-kinase inhibitors is a primary consideration for the Cellcetuix (OTCMKTS:CTIX)

About 20 years ago I got really excited about a company that was working on a potent TNF-alpha antagonist that had potential for treating a wide range of conditions. The problem was that the drug was thalidomide, a terrible teratogen. As you can imagine, it was hard for many to take this company seriously in late 1993. I understood the story. I understood the science. If I recall correctly, they got compassionate use approval for treatment of leprosy but were really focused on getting approval for treating multiple myeloma. Long story short- that company was Celgene. And that 10,000 shares I owned in September of 1993 (about $70,000 worth) would now be worth $23,591,443.67 if I am to believe this historical calculator:

Celgene calculator

I'd like to tell you that I can verify this because this is the value of my account but I can't. I sold Celgene for a small gain because I was looking for more near-term price action and saw what I thought were some really great short term opportunities. Impatience of youth! Fortunately, I got some friends in who were more patient than I and they made millions.

I'm older (but not that old), more patient, maybe a bit more forgetful, and very, very confident that I will be selling my Cellceutix shares at prices much, much higher than $7.50.

Best of luck!

Doc,

thanks for the reply and the link. I just dipped into the link and decided better to read it tomorrow with a fresh brain.

I emailed Leo Ehrlich a few months ago about prospects for a clinical trial. I received a prompt but noncommittal reply. Subsequent PRs make me optimistic about time frame. My son-in-law is being treated mainly at Dana Farber. I am hoping that when B OM trials begin, DF will be one of the locations.

best,
Tom
Tom- I'm sorry to hear about your son-in-law. I'd like to think that B-OM could potentially be preventative for some and palliative for others but that may be wishful thinking. I hesitate to think 'curative' because to me that suggests that the patient has developed lesions and the medicine 'fixes' the lesions. Much better if we can prevent it and limit the tissue damage. If B-OM can limit the severity and duration of the lesions then patients will do so much better.

Unfortunately, it's unlikely that B-OM will be approved at the time your son-in-law could benefit from it. Also, for as promising as drugs such as B-OM may look in early trials, most do not make it to market. I'm extremely optimistic but we don't have enough data to know for sure.

Here's a link that you may find helpful:

Prevention and Treatment of Oral Mucositis

Best of luck.
A slow smoking Chillin Moose cigar. It starts out a bit rough but the closer to the end the better the smoke.

Anyway, not my choice cigar but an example of how things can change. If you're trying to valuate a company in whole thinking everything they're working on will be passed with flying colors I think you're putting the cart way before the horse. When I first started reading your post I went into hyper drive trying to understand where you were coming from.

We're at step two being in Phase 1 with K. The expansion and visibility Kevetrin gains (and has gained) with successful efficacy is immeasurable at this point imo. Considering combination therapies and other trials are already standing by. Not a done deal but reason to be optimistic. The anticipation is clear but I ere on the side of patience.

A little patience doesn't hurt.

Just going from memory I figured a pps of around $4 - $4.75 for ph2b for B conclusion. I may be more conservative than most. That's PRE data btw. providing all goes as expected.

Interesting post BioDoc
Thank you both for zoning in on oral mucositis. My son-in-law will undergo radiation and chemotherapy before undergoing a bone marrow or hematopoietec stem cell cell transplant in an estimated 12 months. A certain side effect is the oral mucositis. He has myelofibrosis, a form of bone marrow cancer.

I think what both of you are touching on comes down to whether B can be effective as palliative or curative. I will post a link that goes into medical terminology way over my head. I hope that one of you or someone here can determine which way brilacidin is likely to be effective.

http://onlinelibrary.wiley.com/doi/10.1046/j....784.x/full

TIA, Tom
I have said it before and I will say it again. Nobody calls it like TheDane...

And as we grow nearer to the B report some are already straddling the line on the field and that's ok.
Mark me in the column for equivalence and a more than ever fired up Leo emerging.


Buyout would probably not occur until some of combo therapies with K are wrapping up phase 2. Don't want another PolyHeist.
Perhaps reformulate is either the wrong word or too strong a word. Maybe 'tweak' would be better word. At any rate, I can't imagine Menon staying with 28 days without at least making an attempt to get that number down, but if B-OM's 28 day dosing regimen turns out to be the most efficacious than so be it.
A "little higher" because that's when the $7.25 buyout occurs?
It's getting pretty interesting when we get a bashing campaign saying the company will be bought for $7.25 in the next year. Normally what you hear from a bash is "CEO is a liar" or "the company is worthless" and such like that. Now we have, "no, CTIX is not worth $3billion and will be bought out for $7.25/ share within 12 months.

Excellent strategy to drive investors away!

Go CTIX!
Hi J, I am not all that bullish about anything significant happening on/or before the September 9 conference, but Leo is probably holding some tidbits for it.

However, IMHO, everything changes starting in Mid-November 2014. Actaully me and Big K kinda agree on one thing, he sees $6.00 in the spring of 2015, I see a little higher by the summer of 2015.
What is the significance of the November date?
Big K, just a difference of opinion. The current market value of CTIX, all in is about 260 Million. In your opinion the current market value should be 3.2 Billion.

I've stated the current price should be $4 to $4.50, thereby, all in, its 680 Million and Lilly will buy us out within the next 9 months for 7.25 MAX, or about 1.2 Billion.

You cannot value and compare CTIX, with K in 1 to a drug company with a drug in 3. Massive difference in valuations. If K,P,B where all in 3, its a totally different story and the stock would not be selling at $2.05.

We get bought out because of the enormous potential and because CTIX has many eyes on it.

Anyway, all the best to you and your wife, enjoy your evening. Although we may have some differences of opinion, ultimately we are on the same team, I am putting my money where my mouth is, as I continue to buy every week, and whatever happens we will all make money with CTIX, it just seems to be a question of when and how much. IMHO, very soon, fireworks start the end of November.

All the best.
I'd be surprised if they reformulate B-OM for a shorter course. It makes sense to me to use an oral rinse until the tissues are no longer vulnerable. Either way, I'm extremely optimistic.

I totally agree with you about K and B. I have the most uncertainty about P though the animal studies are really impressive. Why is Prurisol so effective whereas abacavir does nothing? Still a mystery to me though I'm perfectly happy to go along for the ride. I trust management's judgement- I can wait for the data.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Albertsons Welcomes Once Upon a Coconut Nationwide

Updated Category News Views 4

Coconut Water Takes Over Grocery Aisles You know, for all the cautious optimism I wield, this here is a move that shows real muscle in the world of coconut water—I mean, slamming into Albertsons' grocery empire is no small potatoes! Once Upon a Coconut has landed its premium hydration cans across all the banners under this giant retailer. From that good ol' familiar...

Continue Reading
Crystal Risotti: Leading IT Compliance in Healthcare

Updated Category News Views 1

A Journey Marked by Dedication and Expertise In the demanding world of healthcare technology, where regulations can make or break a company, Crystal Risotti has carved out a space for herself as a leader. Over the last 30 years, she's developed a reputation for blending regulatory expertise with practical business strategies. Her recognition as a Pinnacle Professional of...

Continue Reading
World Fire Congress 2026 Champions Global Fire Safety

Updated Category News Views 1

Rethinking Fire Safety with a Global Mindset The 2026 World Fire Congress wrapped up in London, signaling a big shift in how we tackle fire safety. Over 60 nations were represented, and they all walked away singing the same tune: if we’re going to handle these ever-mounting fire risks, we have to lean on each other a lot more. Next stop on this crusade? The flashy city...

Continue Reading
Flex Dental Solutions Adds BNPL, Surcharging to FlexPayments

Updated Category News Views 2

Diving into Dental Finances: A New Moneymaker? It's about time someone shook up the dental payment scene, and Flex Dental Solutions seems to be the one doing it. They rolled out some intriguing new features for their FlexPayments platform aimed squarely at dental practices using Open Dental. What we're seeing here is their attempt to bridge a couple of financial headaches...

Continue Reading
Veteran Marketer Joins The Wisory's Advisory Board

Updated Category News Views 1

Tyrrell Schmidt Joins The Wisory's Board Out of the blue, The Wisory has snatched Tyrrell Schmidt right off the retirement bench. This doesn't seem like just another board seating; it smells like a calculated power play. Schmidt, fresh from her heavyweight stint as Global CMO at TD Bank, adds a spicy dose of marketing prowess to The Wisory's already loaded Advisory Board....

Continue Reading
Step Inside Henson's Creature Shop Magic in NYC

Updated Category News Views 0

Unlock Puppet Magic with Jim Henson Tours Puppet fans, let me tell you, there's something going on in Queens, NY that's got both nostalgia and innovation scribbled all over it. We're talking about the legendary Jim Henson's Creature Shop opening its doors. If you're looking to relive the magic that helped shape a generation, get ready to dive into a world where creativity...

Continue Reading
RealNex Navigator Upgrades Unveil Vast CRE Capabilities

Updated Category News Views 4

The Dawn of a New Navigator for CRE RealNex is unleashing a storm of enhancements to its Navigator platform, shaking up the commercial real estate (CRE) scene. Their latest upgrades are setting a new precedent for how brokers use technology to sharpen their game, handle transactions, and strategize in a market that never sleeps. Diving Deep into the Latest Upgrades First...

Continue Reading
GBI Bio's New CEO Jesse McCool to Propel Growth

Updated Category News Views 3

Jesse McCool stepping into GBI's CEO shoes is the kind of move that makes you sit up straight and take notice. Let me tell you, the biomanufacturing scene is buzzing with this appointment, and McCool's got his work cut out for him in leading GBI Biomanufacturing's shift towards commercial-scale operations while expanding their early-stage biotech portfolio. A Veteran in...

Continue Reading
USFCR Wins 2026 Award for Federal Contracting Services

Updated Category News Views 3

Award-Winning Federal Contracting Strategies News from Clearwater, Florida: US Federal Contractor Registration (USFCR) just bagged the 2026 nod from Gov Business Review as the Federal Contracting Services of the Year. Now that's a feather in the cap worth talking about. This isn't some hallway compliment, folks. It's a signal that they've nailed how to get businesses...

Continue Reading
Rare Collectibles Highlight Morphy's Auction on Oct 4

Updated Category News Views 2

Anticipation Builds for Morphy's Auction Event Morphy's upcoming event on October 4th is all about tapping into the era of revved engines, gleaming gasoline signs, and some history that could put Hollywood tales to shame. The auction isn't just a stroll down memory lane; it features over 650 lots, each a time capsule of America's automotive past. From Al Capone's ritzy...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover XenDex: Pioneering DeFi Solutions for XRP Ledger

Updated Category News Views 254

Unlocking New Possibilities with XenDex on the XRP Ledger The Ripple (XRP) Ledger has been a standout in the realm of blockchain technology for over a decade, renowned for its speedy transactions, minimal costs, and scalability. Yet, as the landscape of decentralized finance (DeFi) continues to progress, gaps remain. Unlike some of its competitors, such as Ethereum and...

Continue Reading
HALO Dream Inc. Welcomes Child Craft to Its Growing Family

Updated Category News Views 188

HALO Dream Inc. Expands Portfolio with Child Craft Acquisition HALO Dream Inc., a well-respected leader in juvenile sleep products, has recently announced an exciting new acquisition. The company, known for its innovative sleep solutions, has now added Child Craft to its esteemed portfolio. Child Craft is renowned for its quality wood nursery furniture, catering to the...

Continue Reading
Cellectar Biosciences Achieves Compliance with Nasdaq Rules

Updated Category News Views 118

Cellectar Biosciences Achieves Nasdaq Compliance Cellectar Biosciences, Inc. (NASDAQ: CLRB), a leading late-stage clinical biopharmaceutical firm, recently announced that it has regained compliance with the Nasdaq Listing Rule 5250(c)(1). This significant development comes after the company submitted critical financial documents related to its operations. The official...

Continue Reading
EROAD and Medline Strengthen Their Commitment to Innovation

Updated Category News Views 53

EROAD Strengthens Partnership with Medline EROAD, a global leader in fleet management and telematics solutions, proudly announces the renewal of its partnership with Medline. This collaboration highlights both companies’ shared commitment to innovation and sustainable operations. The renewed agreement is expected to enhance customer service and drive growth through...

Continue Reading
Biodexa Pharmaceuticals Prepares for Upcoming General Meeting

Updated Category News Views 176

Biodexa Pharmaceuticals Prepares for Upcoming General Meeting Biodexa Pharmaceuticals PLC is gearing up for an important milestone as it announces its General Meeting. With its commitment to advancing biopharmaceutical innovations, the company is poised to share vital updates and resolutions that reflect its strategic direction. The meeting will take place on May 2, 2025,...

Continue Reading